Monitoring Symptoms During Melanoma Immunotherapy

Investigating Real-Time Immunotherapy Symptoms Study

Recruiting N/A Interventional Study
Cancer Melanoma (Skin Cancer) Immunotherapy
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Supportive Care
Participants needed
40 (estimated)
Sponsor
University of Pittsburgh · Other
Who this trial is looking for

This trial is looking for adults with melanoma who are receiving a specific cancer treatment called immune checkpoint inhibitors. Participants will use a smartphone and wear an activity tracker to report their symptoms and help improve how they feel during treatment.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am 18 years old or older
  • I am receiving immune checkpoint inhibitor therapy for melanoma
  • I can read and write in English
  • I own and use a smartphone for study apps

You may not be able to join if

  • I am under 18 years old
  • I cannot read and write in English

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial
The goal of this study is to evaluate the feasibility of using information from wearable devices and self-reported symptoms to remotely monitor patients during immunotherapy. The main questions it aims to answer are: * Is the digital remote patient monitoring tool feasible and acceptable to patients? * Do the alerts and guidance improve symptom management, quality of life, and engagement with the…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * receiving immune checkpoint inhibitor therapy at UPMC Hillman Cancer Center for melanoma; * age 18 years or older; * ability to read and write in English; * owns and uses a smartphone capable of running study applications Exclusion Criteria: * under 18 years old; and * unabl…
Contacts

Carissa A Low

412-623-5973

lowca@upmc.edu

CONTACT

Krina C Durica

duricak@upmc.edu

CONTACT